Title:
胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体
Document Type and Number:
Japanese Patent JP2007534702
Kind Code:
A
Abstract:
The presently disclosed subject matter provides derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) that are characterized by substantially reduced cyclooxygenase inhibiting activity, yet retain the ability to interact with and modulate the activities of other polypeptides such as the class of peroxisome proliferators-activated receptors (PPARs) and γ-secretase. Also provided are methods of using the derivatives to treat pathological disorders.
Inventors:
Laurence J. Marnet
Jeffrey J. Pulsakie Wicks
Andreus. Felts
Chuan Ji
Jeffrey J. Pulsakie Wicks
Andreus. Felts
Chuan Ji
Application Number:
JP2007509739A
Publication Date:
November 29, 2007
Filing Date:
April 26, 2005
Export Citation:
Assignee:
VANDERBILT UNIVERSITY
International Classes:
A61K31/165; A61K31/167; A61K31/192; A61K31/194; A61K31/336; A61K31/4015; A61K31/405; A61K31/4409; A61K31/5375; A61P35/00; C07C57/62; C07C63/66; C07C233/11; C07C235/34; C07C247/16; C07C317/44; C07C323/62; C07D207/46; C07D209/26; C07D213/40; C07D295/10; C07D303/36
Domestic Patent References:
| JP2004510762A | 2004-04-08 | |||
| JP2004510762A | 2004-04-08 |
Foreign References:
| WO2002020478A1 | 2002-03-14 | |||
| WO2004020409A1 | 2004-03-11 | |||
| DE10163426A1 | 2003-07-03 | |||
| US20030195244A1 | 2003-10-16 | |||
| US3196162A | 1965-07-20 | |||
| WO2002008188A1 | 2002-01-31 | |||
| WO2002020478A1 | 2002-03-14 | |||
| WO2004020409A1 | 2004-03-11 | |||
| DE10163426A1 | 2003-07-03 | |||
| US20030195244A1 | 2003-10-16 | |||
| US3196162A | 1965-07-20 | |||
| WO2002008188A1 | 2002-01-31 |
Other References:
JPN6011031029; Ｔｏｕｈｅｙ，Ｓ． ｅｔ ａｌ: Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｃａｎｃｅｒ Ｖｏｌ．３８, 2002, ｐ．１６６１-１６７０
JPN6011031032; Ｂａｈｎｅｒ，ＣＴ． ｅｔ ａｌ: Ｊｏｕｒｎａｌ ｏｄｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．１６， Ｎｏ．４, 1973, ｐ．４２１-４２５
JPN6011031035; Ｈａｒｅ，Ｌ．Ｅ． ｅｔ ａｌ: Ｊｏｕｒｎａｌ ｏｆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｓｃｉｅｎｃｅｓ Ｖｏｌ．６６， Ｎｏ．３, 1977, ｐ．４１４-４１７
JPN6011031038; Ｎｉｘｏｎ，Ｊ．Ｂ． ｅｔ ａｌ: Ｐｒｏｓｔａｇｌａｎｄｉｎｓ， Ｌｅｕｋｏｔｒｉｅｎｅｓ ａｎｄ Ｅｓｓｅｎｔｉａｌ Ｆａｔｔｙ Ａｃｉｄｓ Ｖｏｌ．６８, 2003, ｐ．３２３-３３０
JPN6011031029; Ｔｏｕｈｅｙ，Ｓ． ｅｔ ａｌ: Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｃａｎｃｅｒ Ｖｏｌ．３８, 2002, ｐ．１６６１-１６７０
JPN6011031032; Ｂａｈｎｅｒ，ＣＴ． ｅｔ ａｌ: Ｊｏｕｒｎａｌ ｏｄｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．１６， Ｎｏ．４, 1973, ｐ．４２１-４２５
JPN6011031035; Ｈａｒｅ，Ｌ．Ｅ． ｅｔ ａｌ: Ｊｏｕｒｎａｌ ｏｆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｓｃｉｅｎｃｅｓ Ｖｏｌ．６６， Ｎｏ．３, 1977, ｐ．４１４-４１７
JPN6011031038; Ｎｉｘｏｎ，Ｊ．Ｂ． ｅｔ ａｌ: Ｐｒｏｓｔａｇｌａｎｄｉｎｓ， Ｌｅｕｋｏｔｒｉｅｎｅｓ ａｎｄ Ｅｓｓｅｎｔｉａｌ Ｆａｔｔｙ Ａｃｉｄｓ Ｖｏｌ．６８, 2003, ｐ．３２３-３３０
JPN6011031032; Ｂａｈｎｅｒ，ＣＴ． ｅｔ ａｌ: Ｊｏｕｒｎａｌ ｏｄｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．１６， Ｎｏ．４, 1973, ｐ．４２１-４２５
JPN6011031035; Ｈａｒｅ，Ｌ．Ｅ． ｅｔ ａｌ: Ｊｏｕｒｎａｌ ｏｆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｓｃｉｅｎｃｅｓ Ｖｏｌ．６６， Ｎｏ．３, 1977, ｐ．４１４-４１７
JPN6011031038; Ｎｉｘｏｎ，Ｊ．Ｂ． ｅｔ ａｌ: Ｐｒｏｓｔａｇｌａｎｄｉｎｓ， Ｌｅｕｋｏｔｒｉｅｎｅｓ ａｎｄ Ｅｓｓｅｎｔｉａｌ Ｆａｔｔｙ Ａｃｉｄｓ Ｖｏｌ．６８, 2003, ｐ．３２３-３３０
JPN6011031029; Ｔｏｕｈｅｙ，Ｓ． ｅｔ ａｌ: Ｅｕｒｏｐｅａｎ Ｊｏｕｒｎａｌ ｏｆ Ｃａｎｃｅｒ Ｖｏｌ．３８, 2002, ｐ．１６６１-１６７０
JPN6011031032; Ｂａｈｎｅｒ，ＣＴ． ｅｔ ａｌ: Ｊｏｕｒｎａｌ ｏｄｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．１６， Ｎｏ．４, 1973, ｐ．４２１-４２５
JPN6011031035; Ｈａｒｅ，Ｌ．Ｅ． ｅｔ ａｌ: Ｊｏｕｒｎａｌ ｏｆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｓｃｉｅｎｃｅｓ Ｖｏｌ．６６， Ｎｏ．３, 1977, ｐ．４１４-４１７
JPN6011031038; Ｎｉｘｏｎ，Ｊ．Ｂ． ｅｔ ａｌ: Ｐｒｏｓｔａｇｌａｎｄｉｎｓ， Ｌｅｕｋｏｔｒｉｅｎｅｓ ａｎｄ Ｅｓｓｅｎｔｉａｌ Ｆａｔｔｙ Ａｃｉｄｓ Ｖｏｌ．６８, 2003, ｐ．３２３-３３０
Attorney, Agent or Firm:
Toru Ishikawa